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Summary The availability of antibodies which recognise p53 protein in paraffin-embedded tissue has created
the opportunity to use immunohistochemistry to study the expression of p53 in a wide variety of clinical
material. In this paper we have investigated the relationship between the type of fixative and the pattern ofp53
staining in mammary carcinoma. Optimal results were obtained from breast tissue fixed in phenol formol
saline, methacarn or cold formol saline with positive staining for stabilised p53 protein occurring in 69/95
(73%) cases studied. Care must be taken in the interpretation of these results since positive staining for p53
protein is not always indicative of mutation of the p53 gene. Furthermore, a range of staining patterns is seen
in mammary carcinomas, making interpretation difficult. Assessment of staining needs to be standardised in
order that different studies can be compared. However, in breast carcinoma, p53 immunohistochemistry
appears to give information relating to tumour grade and, independently, to prognosis.
It is now well recognised that abnormalities in the p53 gene
play an important role in many human cancers (Levine et al.,
1991). Although wild-type p53 protein has a short half-life,
many mutations stabilise the protein, thus making it
amenable to detection by immunohistochemistry. Initially, it
was thought that all immunohistochemically detected protein
was mutant. It is becoming increasingly apparent, however,
that this is not so. Increase in expression of the normal
protein can occur in response to DNA damage (Kastan et
al., 1991; Hall et al., 1993; Rasbridge et al., 1993) and, as
shown by both Hall et al. and Rasbridge et al., excessive
amounts of normal protein can be detected by immunohisto-
chemistry. It is also apparent, from our studies, that the
method of fixation, including both the fixative solution and
temperature, affects the stability of p53 protein in breast
carcinoma tissue. This finding may, in part, explain the wide
range of positive staining reported in mammary carcinoma in
the literature. In this study we have evaluated the immuno-
histochemical detection of p53 protein in mammary car-
cinomas fixed by a variety of methods. Regardless of the
method offixation, immunostaining for p53 produces a range
of staining patterns in mammary carcinomas, making objec-
tive assessment difficult and further contributing to the dis-
crepancies of results in reported studies. In order to further
evaluate this aspect we have tried to analyse the different
staining patterns seen and relate them to the morphological
features of the tumours.
Materials and methods
Surgical specimens of breast tissue containing carcinoma
were received fresh in the laboratory 15 min after removal
from the patient. After standard pathological assessment and
sampling for routine histology and hormone receptor assay,
and if sufficient tumour was available, multiple slices, on
average measuring 1 cm2, were taken and placed in a variety
of fixatives (Table I). Cytosols were prepared from frozen
tissue after homogenisation using a microdismembrator
(Braun, Melsungen, Germany) according to the instructions
in the Abbott enzyme immmunoassay kit (Abbott Labora-
tories, Maidenhead, Berkshire, UK). The protein concentra-
tion of the cytosol extracts was determined by a dye-binding
assay (Bradford, 1976).
Following fixation tissue samples were processed routinely
on a VIP tissue processor. This consisted of dehydration in
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ethanol (six changes), clearing in xylene (three changes) and
paraffin wax impregnation (four changes), the entire process
taking 11 h. The tissues were then embedded and sectioned
for routine histology and immunohistochemistry. Subsequent
to the fixation study tissue from 95 consecutive cases of
infiltrating mammary carcinoma and 20 cases of pure in situ
or predominantly in situ carcinoma with minimal invasion
(<2 mm maximum diameter) was fixed in phenol formol
saline for evaluation of the different staining patterns seen
with the p53 antibody.
Tumour typing andgrading
Infiltrating tumour types were classified according to a
modification of the WHO (1982) system. Tumour grading
was carried out on all infiltrating ductal carcinomas and
tumours of special type. Infiltrating lobular carcinomas were
not graded. The histological grading was based on the
method of Bloom and Richardson as modified by Elston and
Ellis (1991). Cases of in situ ductal carcinoma were classified
as comedo when composed of large pleomorphic cells,
usually with areas of extensive necrosis, or non-comedo when
composed of small or intermediate-sized cells with minimal
or no necrosis, usually with a cribriform or micropapillary
pattern (Bobrow et al., 1993).
Immunohistochemistry
Sections of 3 ym were cut and floated onto glass slides coated
with poly-L-lysine and allowed to dry overnight. Heat was
not used to stick the tissue sections on to the glass as this can
Table I Detailed components of fixatives
Fixative Components
Phenol formol saline 4% formaldehyde, 2% phenol, 0.9%
sodium chloride
Formol saline 4% formaldehyde, 0.9% sodium
chloride
Methacarn Methanol-chloroform-acetic
acid (6:3:1)
Neutral buffered formalin 4% formaldehyde, 0.4% sodium
dihydrogenorthophosphate, 0.65%
disodiumhydrogenorthophosphate
Neutral bufferedphenol 4% formaldehyde, 0.4% sodium
formalin dihydrogenorthophosphate, 0.65%
disodiumhydrogenorthophosphate,
2% phenol
Formolcalcium 4% formaldehyde,1% calciumchloride
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denature the p53 protein. Sections were dewaxed and
endogenous peroxidase activity was blocked with 0.2% hyd-
rogen peroxide. The anti-p53 polyclonal antibody CM-1
(Midgley et al., 1992) was used, with a peroxidase-conjugated
streptavidin-biotin technique. The best results were obtained
when the antibody CM-I was diluted 1:1500 and applied for
1 h at room temperature. Biotinylated goat anti-rabbit
antiserum (Dako, High Wycombe, UK) diluted 1:400 was
applied for 30min at room temperature followed by strep-
tavidin-biotin-peroxidase complex (Dako) for 30 min.
Diaminobenzidine (DAB) was used as chromogen to detect
the peroxidase activity following the antibody-antigen reac-
tion. The nuclei were lightly counterstained with haematoxy-
lin.
Assessment ofthe staining patterns
Immunohistochemistry (Table II) The presence or absence
of staining and depth of colour was noted, as well as the
number of cells showing a positive reaction and whether the
staining was nuclear or cytoplasmic. The depth of colour was
recorded as pale, medium or dark according to how easily it
was seen and the number of positive malignant cells was
assessed as a percentage of the whole tumour. The tumours
were then categorised as weak, moderate or strong stainers
according to the criteria in Table II.
Assessment offixatives Sixteen tumours were of sufficient
size to allow a number of 1-cm2 slices to be fixed in a variety
of ways. Eight of these tumours (Table III) stained positively
for p53 and the quality of the immunohistochemical staining
was assessed in these. Assessment included the strength of
Table II Description of staining patterns
Strong
Moderate
Weak
Scattered
Cytoplasmic
Negative
Dark nuclear staining that is easily visiblewith a
low-power objective and involves > 50% ofcells
Focal darkly staining areas, (<50% ofcells) or
moderate nuclear stainingof> 50% ofcells
Focal moderate stainingin <50% ofcells, or pale
nuclear staining in any proportion ofcells not
easily seen under a low power
Dark nuclear staining ofwidely scattered cells
Tumours that show only cytoplasmic staining
Tumours that show none ofthe above
staining, the site of staining within the cells and the presence
of background staining.
Enzyme-linked immunosorbant assay (ELISA) A sandwich
immunoassay to measure the level of p53 protein in cytosol
extracts was performed on 18 tumours using monoclonal
anti-p53 antibody DO-1 as the solid phase reagent and poly-
clonal rabbit antiserum CM-1 to p53 to detect the captured
proteins (Vojtsesek et al., 1993). The optical density (OD) at
450 nm was recorded and the results were expressed as OD
units per mg of cytosol protein.
Results
Tissue staining in differentfixatives
The results of the staining in the 8/16 tumours which were
positive for p53 are shown in Table III. The best immunohis-
tochemical staining results were obtained in tissue fixed in
phenol formol saline, in which two of the tumours showed
strong staining, while in four it was weak, with one showing
occasional weak nuclear staining and one showing only
cytoplasmic staining. The next most satisfactory fixative was
formol saline used at 4°C overnight. Again, two of the
tumours showed strong staining, while in three it was weak,
in two it was occasional and in one it was cytoplasmic.
Results with methacarn were also satisfactory, although
fewer of the tumours showed overall weak staining and more
of them had occasional weakly positive nuclei. None of the
other fixatives were entirely satisfactory, with the very worst
results being obtained from formol saline heated to 55°C and
formol calcium at any temperature. Tumours 3, 5 and 6 all
had weak but obvious nuclear staining when fixed in phenol
formol saline or in formol saline at 4°C but in all the other
fixatives the staining was either occasional and weak or
cytoplasmic, or else completely absent. Tissue fixed optimally
gave crisp nuclear staining with little or no background. In
poorly fixed tissue not only was the reaction less crisp but
there was loss of some weak nuclear staining and some
leakage ofprotein from the nucleus into the cytoplasm. Thus,
the total percentage of tumours showing positive nuclear
staining was highest in optimally fixed tissue and lowest in
poorly fixed tissue. Background staining was a problem with
neutral buffered formalin and neutral buffered phenol for-
malin. The morphology of the tissue was also best in the
Table III Evaluation of staining patterns from eight p53-positive tumours
ways showing detailed results for individual tumours
fixed in a variety of
Tumour PhF FS4° Meth FSRT NBF NBPhF FS550 FCRT FC550
1 0 0 0 0 - - - - -
2 + 0 0 - C C - - -
3 + + 0 - 0 C - 0 +
4 C C ++ C 0 C C + -
5 + + 0 C C C - C C
6 + + - 0 - + 0
7 +++ +++ +++ ++ +++ + C 0 -
8 +++ +++ +++ +++ ++ ++ ++ + +
Staining intensity
Strong + + +
Moderate + +
Weak +
Occasional and weak 0
Cytoplasmic C
Negative
Type offixative and temperature
PhF Phenol formol saline - 4h at room temperature
FS4° Formol saline - 24 h at 4°C
Meth Methacarn -3 h at room temperature
FSRT Formol saline - 24 h at room temperature
NBF Neutral buffered formalin - 24 h at room temperature
NBPhf Neutral buffered phenol formol saline - 4 h at room temperature
FS550 Formol saline - 1 h 30 min at 55°C
FCRT Formol calcium - 24 h at room temperature
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fixatives which optimally preserved antigenicity. Very
occasional nuclear staining was seen in apparently normal
epithelial tissue immediately adjacent to some tumours.
Otherwise, normal epithelial elements in tissue surrounding
tumours were negative in all cases and in all fixatives.
Analysis ofimmunohistochemical staining patterns using
optimumfixation
This was analysed in the 95 infiltrating and 20 in situ mam-
mary carcinomas which were fixed in phenol formol saline.
Sixty-nine (73%) of the 95 infiltrating carcinomas showed
nuclear staining with CM-1. In 25 (26%) of the tumours the
reaction was strong (Figure la) or moderate (Figure lb).
Two cases showed focal cytoplasmic staining only.
Figure 1 a, Strong staining. Dark nuclear staining of greater
than 50% of cells. b, Moderate staining. Dark nuclear staining of
less than 50% of the cells, remaining tumour cells weakly
positive. c, Scattered staining. Dark nuclear staining of widely
scattered cells, remaining tumour cells negative. All photomicro-
graphs were taken at the same magnification.
Tumours showing nuclear staining were analysed accord-
ing to histological type and histological grade (Tables IV and
V). Strong or moderate staining was largely confined to
tumours of ductal not otherwise specified (NOS) type. One
pleomorphic lobular carcinoma also showed this pattern of
staining, as did one mixed tumour. In the latter case the
strong staining was confined to the ductal NOS component.
However, the number of tumour types other than ductal
NOS is too small to reach any firm conclusion about the
relationship between staining pattern and tumour type. There
was a significant association between malignancy grade and
the presence and strength of positive staining (Pearson's cor-
relation coefficient r = 0.676, P<0.001). Moderate to strong
staining was not seen in any of the grade I tumours; it was
present in 7 of the 21 grade II and 21 of the 26 grade III
carcinomas. Conversely, the greatest percentage of negative
tumours was also seen in the grade III carcinomas (16/42,
38%). The individual components of the grading system
(amount of tubule formation, extent of nuclear pleomor-
phism and number ofmitoses) also correlated with the degree
of staining but not as strongly as overall grade. The associa-
tion of staining with differentiation was persistently seen,
even in those tumours with a mixed pattern. There was one
mixed mucoid and grade III ductal carcinoma; the cells of
the ductal carcinoma were more pleomorphic and had a
much higher mitotic rate than in the mucoid component and
the intensity of the staining with the CM-1 antibody was
convincingly stronger.
Five per cent of cases showed isolated, darkly positive
nuclei scattered throughout an otherwise negative tumour
(scattered staining) (Figure 1c). This is a constant finding in
several separate studies in our laboratory and appears to be a
genuine pattern of p53 protein expression. In the analysis of
grade these tumours were included with the moderate
stainers. All negative tumours were excluded from the stati-
stical analysis because lack of staining is not solely an indica-
tion of the presence of normal p53 protein but will also be
seen when both p53 alleles have been lost, or if a particular
mutation has resulted in an extremely rapid disappearance of
the protein.
Ten of 18 cases of pure ductal carcinoma in situ (DCIS)
and the two microinvasive DCIS cases showed positive stain-
ing (Table VI). Strong or moderate staining was seen in 7 of
12 comedo-type DCIS, the remaining five cases being nega-
tive. Only one non-comedo DCIS showed strong staining;
two stained weakly and five were negative. This finding is
consistent with the association of strong staining in high-
grade tumours.
ELISA
There was a highly significant correlation between the
immunohistochemical staining pattern and the ELISA score
for the amount of p53 protein (Table VII). All eight of the
strong (n= 7) or moderate (n= 1) stainers were positive by
the ELISA. These tumours were all infiltrating ductal grade
III carcinomas. The remaining ten carcinomas were negative
by ELISA; five were also negative by immunohistochemistry
and five showed weak or scattered positive staining (rank
correlation coefficient r=0.871, P<0.0001).
Discussion
With the rapid development of a range of antibodies to the
p53 protein which work in fixed tissue (Midgley et al., 1992;
Vojtesek et al., 1992; Bartek et al., 1993) it is now possible to
carry out large retrospective studies of the protein expression
in a variety of human cancers. It is essential, therefore, that
the effect of different types of fixation on antigen preserva-
tion is recognised and the results of staining evaluated in the
light of this knowledge. This study has shown that some
fixatives appear to preserve the antigenicity of the p53 pro-
tein better than others. This particularly applies to tumours
showing only weak nuclear staining.OPTIMISATION OF p53 IMMUNOHISTOCHEMISTRY 29
Table IV Relationship between histological type of tumour and pattern of p53 staining
Type of Strongl Staining pattern
infiltrating tumour No. moderate Weak Scattered Cytoplasmic Negative
Ductal NOS
Grade I 6 0 6 0 0 0
Grade II 28 4 14 3 1 6
Grade III 42 19 4 2 1 16
Special types (grade I)
Tubular 1 0 1 0 0 0
Cribriform 1 0 1 0 0 0
Mucoid 1 0 0 0 0 1
Lobular
Classical 7 0 7 0 0 0
Variant 3 1 2 0 0 0
Mixed
Classical lobular 5 0 4a 0 0 1
+ grade I ductal
Mucoid + grade i1 0 0 0 0
III ductal
Totals 95 25 39 5 2 24
aStaining present in both components in all cases. bStaining present in ductal NOS grade III
component only.
Table V Analysis by grade of tumours showing positive nuclear
staining
Moderatel
Strong scattered Weak Total
Grade I 0 0 12 12
Grade II 1 6 14 21
Grade III 14 8 4 26
59
Pearson's correlation coefficient r = 0.676, P <0.0001.
Table VI Staining pattern of DCIS cases
Strong!
Type Total no. moderate Weak Negative
Comedo 12 7a 0 5a
Non-comedo 8 1 2 5
Total 20 8 2 10
aOne case of microinvasive DCIS in each group.
Table VII Association between immunohistochemical (IHC)
staining and ELISA score
IHC staining OD units per mg of
Number pattern cytosol protein Grade
Samples positive by both ELISA and immunohistochemistry (n = 18)
1 Moderate 0.39 3
2 Strong 0.96 3
3 Strong 2.31 3
4 Strong 0.22 3
5 Strong 0.70 3
6 Strong 0.28 3
7 Strong 0.50 3
8 Strong 0.54 3
Samples negative by ELISA, positive by IHC (n = 5)
9 Scattered
10 Scattered
11 Weak Negative
12 Weak
13 Weak J
2
2
2
1
2
Samples negative by both methods (n = 5)
14 Negative 2
15 Negative 1 3
16 Negative Negative 3
17 Negative 3
18 Negative 3
Rank correlation coefficient r = 0.871, P <0.0001.
In our laboratory it is essential for diagnostic purposes to
have a rapid method of fixation. In the past we have used
formol saline or formol calcium, both for lih at 55°C, in
order to speed up the fixation before the tissues are processed
to paraffin wax. While these procedures gave satisfactory
morphology for diagnostic purposes we have recently found
that this rapid fixation caused a loss of antigenicity of some
nuclear antigens and gave very poor-quality DNA for flow
cytometry. The paper by Hopwood et al. (1989) describing a
novel method of rapid fixation in phenol formol saline
encouraged us to re-evaluate the fixatives used in our
laboratory. We investigated the nine fixatives employed in
this study for their suitability for use with a wide range of
other antibodies as well as their suitability for use in a
diagnostic laboratory with regard to speed of fixation and
preservation of cell morphology (Cooper et al., 1992). As a
result we now use phenol formol saline as our routine
fixative. It is good for the preservation of antigenicity for a
wide range of antibodies, including those to p53. Tissue fixed
in this way has good morphology and fixation is rapid and,
in addition, gives excellent preservation of DNA for use in
flow cytometry and in analyses using the polymerase chain
reaction technique.
Heat was found to be particularly deleterious with regard
to antigen preservation for p53 (Table III) and other nuclear
antigens. Obviously heat cannot be completely excluded from
processing but should be kept to a minimum where possible.
It should not be used during fixation and should not be used
to adhere sections to slides. A suitable tissue adhesive, such
as poly-L-lysine, should be used to coat the slides and sec-
tions dried overnight at room temperature.
In our series of 95 cases of infiltrating carcinoma, fixed
under what we consider to be optimum conditions, the
overall prevalence of positive nuclear staining with the CM-1
was 69/95 (73%). This is high compared with other studies,
but the proportion of tumours showing strong or moderate
staining (32%) is within the range considered to be positive
by authors who have been selective as to what constitutes a
positive result. It may be that the prevalence ofweak staining
was higher in this study because of the attention paid to
optimising the method of fixation. There is no agreement in
the literature as to what constitutes positive staining. Some
authors accept any positive cells (Cattoretti et al., 1988),
others only where staining is seen in more than 20% of cells
(Isola et al., 1992), and yet others insist on widespread
staining before accepting positivity (Davidoff et al., 1991). In
some papers attention is also paid to the strength of staining.
If, however, p53 immunohistochemistry is to be of value in
studying the biology of breast cancer there is a need to reach30 C.J. FISHER et al.
a consensus about the best way to assess the degree of
positive staining so that studies from different centres are
comparable.
The range of staining patterns and the effects of different
fixatives may reflect the variety of structural forms produced
by different mutations in the p53 molecule. Bodner et al.
(1992) concluded from work on cell lines that the pattern of
protein expression in tumour cells detected by immunohisto-
chemistry is dependent upon the type of mutation in the p53
tumour-suppressor gene.
Bartek et al. (1990) consider that the strength of staining is
related to the amount of p53 protein present, and our studies
support this. The 18 cytosols measured by the ELISA in this
study also formed part of a larger series (Vojtesek et al.,
1993) in which the number of positive cells was counted and
the depth of staining considered in order to calculate a
staining index. The index showed a positive association with
the amount of p53 protein measured by the ELISA.
In agreement with other studies we found a good correla-
tion between staining and histological grade. Strong and
moderate staining was only seen in grade II and III tumours
and the majority were grade III. Interestingly, negative stain-
ing was more frequent in grade III tumours. A possible
explanation for this is that many of these tumours have lost
both alleles and, therefore, the ability to make any p53
protein. If this is so the detection of weak staining becomes
more important as its presence excludes tumours which have
lost both alleles. In cases of DCIS strong staining was also
seen more frequently in the comedo pattern composed of
high-grade pleomorphic cells. In contrast to low-grade
infiltrating tumours, which all showed weak staining, five of
the eight low-grade non-comedo DCIS were negative. This
could be because p53 is normal in this pattern of DCIS or, as
most of the lesions were small, perhaps because there were
insufficient tumour cells available to demonstrate focal
positive staining.
As pointed out by Wynford-Thomas (1992), positive stain-
ing does not necessarily indicate the presence of a mutation
in the p53 gene. In a recent paper Mazars et al. (1992) found
mutations in only 18/95 (19%) breast carcinomas, which is
considerably lower than the reported prevalence of positive
immunohistochemical staining. The p53 protein may be
stabilised by other means such as a normal response to DNA
damage (Lane, 1992) or by binding to proteins such as
MDM2 (Oliner et al., 1992) or GADD45 (Kastan et al.,
1992). The complexity of the present situation is well set out
in the recent editorial by Yandell and Thor (1993).
Studies evaluating the prognostic value of p53 immunohis-
tochemical detection have generally shown an association
with poor prognosis (Isola et al., 1992; Thor et al., 1992;
Allred et al., 1993). A recent study from our laboratory
suggests that it is the proportion of tumour cells that stain
positively that is important. Tumours in which the majority
of cells stain for p53 protein have a poorer prognosis than
tumours in which few cells stain and this correlation is
independent of histological grade (Barnes et al., 1993).
In conclusion, caution must be exercised in the evaluation
of p53 protein expression detected by immunohistochemistry.
The stability of the protein is affected by different fixation
methods, and this particularly applies to weak staining.
Negative staining does not necessarily mean that there is no
abnormality in the p53 gene and, conversely, positive staining
does not always indicate mutant protein. There is a need for
the method of assessment of positive staining to be standar-
dised. Despite these limitations, however, p53 appears to give
information relating to tumour grade and independently to
prognosis.
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